BANK VONTOBEL/CALL/ELI LILLY & CO/660/0.1/21.06.24 | Delayed Deutsche Boerse AG 14:02:36 2024-06-19 EDT | ||
| 21.93 EUR | +3.79% |
|
| Current month | +51.66% | ||
| 1 month | +102.87% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
| Date | Price | Change |
|---|---|---|
| 24-06-19 | 21.93 | +3.79% |
| 24-06-18 | 21.13 | -1.03% |
| 24-06-17 | 21.35 | +3.84% |
| 24-06-14 | 20.56 | +0.44% |
| 24-06-13 | 20.47 | +8.25% |
Delayed Quote Deutsche Boerse AG
Last update June 19, 2024 at 02:02 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
Vontobel
|
| WKN | VM1HAJ |
| ISIN | DE000VM1HAJ2 |
| Date issued | 2023-08-22 |
| Strike | 660 $ |
| Maturity | 2024-06-21 (2 Days) |
| Parity | 10 : 1 |
| Emission price | 2.15 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 22.2 € |
|---|---|
| Lowest since issue | 1.74 € |
| Spread | 0.45 € |
| Spread % | 2.03% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
891.5
USD
Average target price
855.4
USD
Spread / Average Target
-4.05%
- Stock Market
- Warrants
- Warrant
